BSE Live
Apr 17, 16:01Prev. Close
152.15
Open Price
153.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 17, 15:58Prev. Close
152.50
Open Price
153.11
Bid Price (Qty.)
148.01 (436)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Sun Pharma Advanced Research Company (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | -345.22 | -388.11 | -222.58 | -203.40 | -151.14 | |
| Net CashFlow From Operating Activities | -362.41 | -429.43 | -69.12 | -208.23 | -151.90 | |
| Net Cash Used In Investing Activities | 157.66 | 391.11 | -548.28 | -29.17 | 1.56 | |
| Net Cash Used From Financing Activities | 200.88 | 42.80 | 616.76 | 229.32 | 159.28 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -3.87 | 4.48 | -0.64 | -8.08 | 8.95 | |
| Cash And Cash Equivalents Begin of Year | 5.06 | 0.58 | 1.22 | 9.30 | 0.35 | |
| Cash And Cash Equivalents End Of Year | 1.19 | 5.06 | 0.58 | 1.22 | 9.30 |
10.02.2026
Sun Pharma Adv Standalone December 2025 Net Sales at Rs 8.45 crore, down 43.33% Y-o-Y
10.02.2026
Sun Pharma Adv Consolidated December 2025 Net Sales at Rs 8.45 crore, down 43.33% Y-o-Y
16.01.2026
17.11.2025
Sun Pharma Adv Consolidated September 2025 Net Sales at Rs 7.86 crore, down 38.88% Y-o-Y
10.02.2026
Sun Pharma Adv Standalone December 2025 Net Sales at Rs 8.45 crore, down 43.33% Y-o-Y
10.02.2026
Sun Pharma Adv Consolidated December 2025 Net Sales at Rs 8.45 crore, down 43.33% Y-o-Y
17.11.2025
Sun Pharma Adv Consolidated September 2025 Net Sales at Rs 7.86 crore, down 38.88% Y-o-Y
12.11.2025
Sun Pharma Adv Standalone September 2025 Net Sales at Rs 7.86 crore, down 38.88% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth